About Altri Biotherapeutics

Altri is a pre-clinical-stage pharmaceutical company focusing on the development of therapeutic monoclonal antibodies (mAbs) and is located in Richmond, VA, in the VA Bio+Tech Park.

Altri has built on 30 years of research on the insulin-like growth factor (IGF) signaling system to develop agonistic mAbs to use this system for cancer treatment. Altri has licensed the patents for targeting the IGFBP-3/TMEM219 pathway for the treatment of human diseases from Virginia Commonwealth University for all indications globally. Altri’s initial target is directed at TNBC, but Altri plans to use the same antibody therapeutics approach to develop related agonistic mAbs targeting metastatic and invasive cancers including lung, colon, pancreatic and liver cancer, melanoma and leukemia. Altri has also filed additional patents for the protection of the use of agonistic mAbs for other indications including cancer and inflammatory diseases.

Company Overview

INNOVATION: Discovery, development and commercialization of novel antibody therapeutics targeting an anti-tumor and anti-metastatic TMEM219 signaling.

STAGE OF BUSINESS: Novel therapeutic antibody drug candidates currently validated in pre-clinical studies, IND-enabling development under preparation. Matching government funding in progress.

Our Research

Asset Profile & Development Plan

Mechanism of Action

IGFBP-3/TMEM219 axis represents a novel anti-tumor and anti-metastatic signaling in TNBC and other cancers including lung, colon, pancreatic and liver cancer, melanoma and leukemia. This novel anti-tumor axis is dysregulated in TNBC mainly owing to the suppression of IGFBP-3, whereas...
Read More TMEM219 anti-tumor signaling remains functional and can be activated by treatment with ALT-101: (1) ALT-101 inhibits growth of TNBC cells but not normal mammary epithelial cells in vitro; (2) ALT-101 induces apoptosis and inhibits migration of TNBC cells only in a TMEM219-dependent manner; (3) ALT-101 inhibits tumor growth and metastasis in orthotopic mouse model and patient derived xenograft (PDX) TNBC models. ALT-101 specifically exerts anti-tumor and anti-metastatic functions in TNBC via induction of apoptosis, suppression of tumor-activated NF-B signaling, inhibition of Bcl-2 family survival proteins, and inhibition of ICAM-1, all tumor-specific factors involved in tumorigenesis and cancer progression.
Read Less

Proof of Concept

ALT-1 is efficacious in multiple metastatic cancer models, including TNBC, shrinks primary tumors and prevents their metastatic spreads in preclinical animal tumor models. There is substantial preclinical evidence showing that ALT-101 is an effective therapeutic drug candidate against other tumors.

Intellectual Property

Exclusive global licenses for targeting the IGFBP-3/TMEM219 pathway for the treatment of human diseases. Altri also filed additional patents for application of the mAbs for other indications including cancer and inflammatory diseases.

Clinical Development Plan

The goal is to pursue at least one of these therapeutic candidates towards IND-filing and Phase I/II clinical trials, while other assets continue their pre-clinical development. IND-enabling studies (process development, large-animal...
Read More toxicology and GMP manufacturing) are planned and awaiting further funding. Ready for key go/no-go IND approval of ALT-101 for TNBC in the fourth quarter of 2022 and Phase Ib/II trial of ALT-101 in 2025.
Read Less


Altri’s technology identifies a novel anti-tumor signaling pathway and related therapeutic targets.

  • Altri established strong preclinical anticancer efficacy data using animal tumor models including Patient Derived Xenografts of lung, colon, prostate and triple-negative breast cancer as well as leukemia.
  • The novel agonistic mAb, ALT-101 has shown profound “anti-tumor” and “anti-metastatic” activity in multiple cancers.
  • ALT-101, is an attractive therapeutic candidate as the development of agonist mAbs has been given more attention in later years. Several agonistic mAbs are under clinical development with CD40 mAbs being the most advanced (six anti-CD40 Abs currently in clinical trials).
  • ALT-101 is a targeted antibody therapy for TNBC as a monotherapy and a combination therapy with chemodrugs and immune checkpoint inhibitors. The treatment paradigm for TNBC has been chemotherapy and radiation, with doxorubicin and paclitaxel as typical first-line agents. Immunotherapy mAbs and PARP inhibitors being newcomers to the market. Overall, approximately 76% of TNBC patients receive chemotherapy. With 40,000+ incident cases of TNBC per year in the US, that equates 30,000+ patients currently receiving chemotherapy who will benefit from ALT-101.

Unmet Medical Need

R&D Pipeline

Lead Discovery POC/Preclinical Phase 1 Phase 2/3
Rare Diseases
Th-1 type inflammatory disease


800 East Leigh St, Suite 1234 Richmond, VA 23219